NATTO - 10 Year Vitamin K study published
10 year study published in December 2017, "Prevalence and Effects of Functional Vitamin K Insufficiency: The PREVEND Study"
"Importantly, a low vitamin K status is not only a clinically relevant risk factor for adverse health outcomes, but may also be a modifiable risk factor. Given the availability of vitamin K supplements, vitamin K insufficiency seems an attractive target for preventive intervention."
http://www.mdpi.com/2072-6643/9/12/1334
"Importantly, a low vitamin K status is not only a clinically relevant risk factor for adverse health outcomes, but may also be a modifiable risk factor. Given the availability of vitamin K supplements, vitamin K insufficiency seems an attractive target for preventive intervention."
http://www.mdpi.com/2072-6643/9/12/1334
Redigert 21.01.2021 kl 06:39
Du må logge inn for å svare
Herman*
04.01.2018 kl 16:26
5615
Antar at MenaQ7 ble brukt, dette er jo et studie som er utført av samme "gjengen" i Nederland som har holdt på med Vitamin K2 studier i en mannsalder.
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
Svensson1
04.01.2018 kl 16:30
5628
No, this was not an intervention study (no supplement was given).
Instead they show that over a 10-year period, people with vitamin K insufficiency is more likely to die both from all-cause and cardiovascular mortality.
Instead they show that over a 10-year period, people with vitamin K insufficiency is more likely to die both from all-cause and cardiovascular mortality.
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
Herman*
04.01.2018 kl 16:57
5616
Aha, thanks for correcting me...:-)
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
Svensson1
04.01.2018 kl 22:41
5556
You are welcome :-)
Another important excerpt from the study -
"We demonstrated that functional vitamin K insufficiency is common in the general population and occurs even more frequently
among the elderly and subjects with hypertension, type 2 diabetes, CKD, and CVD."
Another important excerpt from the study -
"We demonstrated that functional vitamin K insufficiency is common in the general population and occurs even more frequently
among the elderly and subjects with hypertension, type 2 diabetes, CKD, and CVD."
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
Svensson1
14.01.2018 kl 12:34
5400
Here is yet another study on Vitamin K, published in January 2018. Authors include Leon Schurgers and Cees Vermeer.
http://www.mdpi.com/2072-6643/10/1/46/htm
http://www.mdpi.com/2072-6643/10/1/46/htm
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
Disse studiene måler ikke VitK direkte, kun en markør for VitK-balanse, og skiller ikke mellom K1 og K2. Likefullt er det interessant og er en ny indikasjon på at VitK har betydning for kardiovaskulær helse.
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
VITAMIN K2 FOR HEART AND BONE HEALTH
Researchers at the University of California in Los Angeles have begun to understand the link between atherosclerosis and osteoporosis. They seem to be linked to certain regulators, such as osteopontin and matrix GLA-protein, which affect both bone health and the health of the arteries. A protein known as morphogenetic protein-2 was thought to be present only in bone but has been found in the tissue that makes up atherosclerotic plaques.
http://masjcs.com/vitamin-k2-heart-bone-health/
Researchers at the University of California in Los Angeles have begun to understand the link between atherosclerosis and osteoporosis. They seem to be linked to certain regulators, such as osteopontin and matrix GLA-protein, which affect both bone health and the health of the arteries. A protein known as morphogenetic protein-2 was thought to be present only in bone but has been found in the tissue that makes up atherosclerotic plaques.
http://masjcs.com/vitamin-k2-heart-bone-health/
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
Herman*
13.02.2018 kl 22:43
5058
Denne er helt ny:
Konklusjonen først: . "VK2 exerted effective antitumor effects in vivo, and VK2 nanoemulsions modified with sialic acid-cholesterol conjugate enhanced the antitumor activity, suggesting that these VK2 may be promising agents for the prevention or treatment of tumor in patients".
https://www.ncbi.nlm.nih.gov/pubmed/28849577
Evaluation of the antitumor effects of vitamin K2 (menaquinone-7) nanoemulsions modified with sialic acid-cholesterol conjugate.
Shi J1, Zhou S1, Kang L1, Ling H1, Chen J2, Duan L2, Song Y3, Deng Y4.
Author information
Abstract
Numerous studies have recently shown that vitamin K2 (VK2) has antitumor effects in a variety of tumor cells, but there are few reports demonstrating antitumor effects of VK2 in vivo. The antitumor effects of VK2 in nanoemulsions are currently not known. Therefore, we sought to characterize the antitumor potential of VK2 nanoemulsions in S180 tumor cells in the present study. Furthermore, a ligand conjugate sialic acid-cholesterol, with enhanced affinity towards the membrane receptors overexpressed in tumors, was anchored on the surface of the nanoemulsions to increase VK2 distribution to the tumor tissue. VK2 was encapsulated in oil-in-water nanoemulsions, and the physical and chemical stability of the nanoemulsions were characterized during storage at 25 °C. At 25 °C, all nanoemulsions remained physically and chemically stable with little change in particle size. An in vivo study using syngeneic mice with subcutaneously established S180 tumors demonstrated that intravenous or intragastric administration of VK2 nanoemulsions significantly suppressed the tumor growth. The VK2 nanoemulsions modified with sialic acid-cholesterol conjugate showed higher tumor growth suppression than the VK2 nanoemulsions, while neither of them exhibited signs of drug toxicity. In summary, VK2 exerted effective antitumor effects in vivo, and VK2 nanoemulsions modified with sialic acid-cholesterol conjugate enhanced the antitumor activity, suggesting that these VK2 may be promising agents for the prevention or treatment of tumor in patients.
Konklusjonen først: . "VK2 exerted effective antitumor effects in vivo, and VK2 nanoemulsions modified with sialic acid-cholesterol conjugate enhanced the antitumor activity, suggesting that these VK2 may be promising agents for the prevention or treatment of tumor in patients".
https://www.ncbi.nlm.nih.gov/pubmed/28849577
Evaluation of the antitumor effects of vitamin K2 (menaquinone-7) nanoemulsions modified with sialic acid-cholesterol conjugate.
Shi J1, Zhou S1, Kang L1, Ling H1, Chen J2, Duan L2, Song Y3, Deng Y4.
Author information
Abstract
Numerous studies have recently shown that vitamin K2 (VK2) has antitumor effects in a variety of tumor cells, but there are few reports demonstrating antitumor effects of VK2 in vivo. The antitumor effects of VK2 in nanoemulsions are currently not known. Therefore, we sought to characterize the antitumor potential of VK2 nanoemulsions in S180 tumor cells in the present study. Furthermore, a ligand conjugate sialic acid-cholesterol, with enhanced affinity towards the membrane receptors overexpressed in tumors, was anchored on the surface of the nanoemulsions to increase VK2 distribution to the tumor tissue. VK2 was encapsulated in oil-in-water nanoemulsions, and the physical and chemical stability of the nanoemulsions were characterized during storage at 25 °C. At 25 °C, all nanoemulsions remained physically and chemically stable with little change in particle size. An in vivo study using syngeneic mice with subcutaneously established S180 tumors demonstrated that intravenous or intragastric administration of VK2 nanoemulsions significantly suppressed the tumor growth. The VK2 nanoemulsions modified with sialic acid-cholesterol conjugate showed higher tumor growth suppression than the VK2 nanoemulsions, while neither of them exhibited signs of drug toxicity. In summary, VK2 exerted effective antitumor effects in vivo, and VK2 nanoemulsions modified with sialic acid-cholesterol conjugate enhanced the antitumor activity, suggesting that these VK2 may be promising agents for the prevention or treatment of tumor in patients.
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
fabian2
09.08.2019 kl 16:26
3165
Hu Hei hvor det går med aksjekursen.....nå trenger vi flere studier....og et lite støttekjøp...
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
fabian2
22.08.2019 kl 00:44
3045
"Trippel K2 er bedre enn alle andre , jeg er ikke i tvil om det"...... står det å lese på internett akkurat nå...... Er dette en konkurrent eller selveste Montgomery som er ute på skrytetur ?
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
fabian2
27.08.2019 kl 10:19
2932
Nå trenger vi flere studier - eller ihvertfall priser
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
fabian2
27.08.2019 kl 11:51
2903
Middelsstor kjøper på 7.20......nå har du sjansen
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
holmes
27.08.2019 kl 13:11
2867
For oss som vurderer kjøp er det dessverre ganske glissent helt opp til 10 kroner
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
aksjen er visst alltid for dyr for kjøperane, så her blir det nok stille til neste kvartalsrapport. Rart at det ikke blir starta ett aksjonæropprør mot denne griske og inkompetente ledelsen.
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
fabian2
27.08.2019 kl 22:50
2785
Aksjonæropprør ? Kun de som har flertallet bestemmer. Og det er ikke småaksjonærene. - Sannsynligvis klokt å selge mens man overhodet kan.
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
Eller kjøpe, så lenge det finnes idioter som selger under 10,-
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
fabian2
28.08.2019 kl 21:46
2669
Det er ikke pent å kalle de som prøver å berge noe av sparepengene sine for "idioter"........-En eneste liten kjøper på 8.00 i dag ...men rikelig med de som vil selge. Tallenes tale er tydelig.
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
Jono
29.08.2019 kl 18:54
2607
som jeg har skrevet til deg i en annen tråd, om du og meg -- hadde tatt kontrollen, sikkert villet sparket styre og ledelse, men hva skulle vi videre gjort?
må innrømme, at jeg hadde en "gåte" på lur, men tror ikke jeg vet hvem du var lengre, samme det, men min gåte var, at jeg selv er glad i rødvin, du i Vodka! :-)
fra spøk til alvor, så håper jeg du forstår min dårlige humor, men om du gjør -- så er jo det veldig bra for både deg og meg, ikke sant! ? :-)
må innrømme, at jeg hadde en "gåte" på lur, men tror ikke jeg vet hvem du var lengre, samme det, men min gåte var, at jeg selv er glad i rødvin, du i Vodka! :-)
fra spøk til alvor, så håper jeg du forstår min dårlige humor, men om du gjør -- så er jo det veldig bra for både deg og meg, ikke sant! ? :-)
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
fabian2
20.11.2019 kl 20:10
2231
Ifølge trollet er det bare idioter som selger under 10
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
fabian2
20.11.2019 kl 21:17
2203
Da er det jo bare idioter som har solgt i månedsvis nå.......bare tullinger som har vært inne i Natto ?....?
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
fabian2
20.11.2019 kl 21:21
2195
Det trollet prøver å si , er jo at Natto har vært en oppsamlingsplass for evneveike
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare
fabian2
22.11.2019 kl 07:35
2077
------7.75------det er nå så ,........ men 118 lesere siden onsdag kveld, "vanvittig" stor interesse for bittelille Natto.....pussig
Redigert 21.01.2021 kl 00:28
Du må logge inn for å svare